Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Capital Leases (2016 - 2017)

Historic Capital Leases for Ekso Bionics Holdings (EKSO) over the last 3 years, with Q1 2017 value amounting to $125000.0.

  • Ekso Bionics Holdings' Capital Leases fell 3932.04% to $125000.0 in Q1 2017 from the same period last year, while for Mar 2017 it was $125000.0, marking a year-over-year decrease of 3932.04%. This contributed to the annual value of $226000.0 for FY2015, which is N/A changed from last year.
  • Ekso Bionics Holdings' Capital Leases amounted to $125000.0 in Q1 2017, which was down 3932.04% from $166000.0 recorded in Q3 2016.
  • In the past 5 years, Ekso Bionics Holdings' Capital Leases registered a high of $226000.0 during Q4 2015, and its lowest value of $125000.0 during Q1 2017.
  • In the last 3 years, Ekso Bionics Holdings' Capital Leases had a median value of $186000.0 in 2016 and averaged $181800.0.
  • Over the last 5 years, Ekso Bionics Holdings' Capital Leases had its largest YoY gain of 3932.04% in 2017, and its largest YoY loss of 3932.04% in 2017.
  • Quarter analysis of 3 years shows Ekso Bionics Holdings' Capital Leases stood at $226000.0 in 2015, then decreased by 26.55% to $166000.0 in 2016, then fell by 24.7% to $125000.0 in 2017.
  • Its Capital Leases was $125000.0 in Q1 2017, compared to $166000.0 in Q3 2016 and $186000.0 in Q2 2016.